Tim Peara has been appointed director of finance and will be joining the management team at Bridge Therapeutics.
 
Mr. Peara has more than 30 years of experience with institutional investments and technology start-ups. He has negotiated and structured investments, conducted due diligence, and built financial models for companies in finance, energy tech, and industry. Mr. Peara has contributed to the growth and strategy of industry leaders, including Wells Fargo, Prudential, Lehman Brothers, Koch Industries, GE, Bechtel and United Technologies.
 
The company, based in Birmingham, AL, is researching chronic pain alternatives to help reduce the impact of the opioid epidemic. The pharma company is currently pursuing FDA and European Medicines Agency (EMA) approval of a patented drug combination for the treatment of chronic pain in opioid-experienced patients.
 
“I believe Bridge Therapeutics is well positioned to provide safer alternatives that will help curb this current opioid epidemic,” said Mr. Peara. “I’ve worked with many industry titans and I’ve followed the rapid growth of Bridge Therapeutics. It’s even more exciting to work with Bridge Therapeutics on bringing their patented chronic pain medications to the market.”